文献速递乳腺外科

早期乳腺癌腋窝手术降阶梯:将SOUND与INSEMA试验转化为临床实践

De-escalation of Axillary Surgery in Early Breast Cancer: Translating SOUND and INSEMA into Clinical Practice.
PubMed 文献 · Ann Surg · 2026-10-12

该前瞻性研究评估了绝经后HR+/HER2-早期乳腺癌患者中省略前哨淋巴结活检(SLNB)的可行性。最终病理显示34例(8%)具有高风险特征,14例(3.2%)接受了SLNB,其中2例有前哨淋巴结转移。中位随访7.7个月,无腋窝复发。结论认为,采纳SOUND、INSEMA和BOOG 13-08数据后,97%的符合条件的绝经后患者可安全省略SLNB。

要点

  • 绝经后HR+/HER2-、cT1-2N0、1-2级、腋窝超声正常的乳腺癌患者可考虑省略SLNB。
  • 最终病理高风险特征(3级、T≥3厘米、HER2+)发生率8%,仅3.2%需补充SLNB。
  • 中位随访7.7个月无腋窝复发,支持该降阶梯策略的短期安全性。

核心结论

  • 在符合SOUND、INSEMA和BOOG 13-08标准的绝经后患者中,97%可成功省略SLNB。

研究设计与样本

  • INSEMA结果公布后,纳入肿瘤大小上限扩大至2.5厘米。

主要发现

  • 中位患者年龄63岁,中位钼靶肿瘤大小0.9厘米,74%为2级。
  • 34例(8%)最终病理具有高风险特征(3级20例;T≥3厘米11例;HER2+3例),14例(3.2%)接受了SLNB,其中2例发现前哨淋巴结转移。
  • 96%的患者接受了放疗(40%全乳,56%部分乳腺),415例(95%)接受辅助内分泌治疗,31例(7%)接受化疗。
  • 中位随访7.7个月,无腋窝复发。

关键数值与推荐

  • 省略SLNB的入选标准:绝经后女性,年龄50-70岁,单灶或多灶,临床1期,1/2级,HR+/HER2-,腋窝超声正常,接受保乳手术。
  • 最终病理显示3级、T≥3厘米、HR-或HER2+的患者需多学科讨论是否行SLNB。

临床怎么用

  • 对于符合SOUND/INSEMA标准的绝经后HR+/HER2-早期乳腺癌患者,可在腋窝超声正常时安全省略SLNB。
  • 术后病理出现高风险特征时,应通过多学科讨论决定是否补充SLNB。

局限性

  • 随访时间较短(中位7.7个月),缺乏长期腋窝复发和生存数据。
  • 研究为单臂前瞻性评估,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To prospectively evaluate how often axillary staging can successfully be omitted in postmenopausal HR+/HER2- patients. BACKGROUND: Three randomized trials showed no difference in recurrence or survival outcomes with omission of sentinel lymph node biopsy (SLNB) in cT1-T2N0 patients with a negative axillary ultrasound (AUS) undergoing breast-conserving surgery (BCS). We prospectively evaluated applicability of this approach. METHODS: From 3/1/24 to 9/1/25, SLNB was omitted in postmenopausal women age 50-70 years with unicentric or multifocal, clinical stage 1, grade 1/2, HR+/HER2- cancers and a normal AUS undergoing BCS. After the results of INSEMA were reported, tumors up to 2.5 cm were included. Patients with pathology showing grade 3, T≥3 cm, or HR- or HER2+ underwent multidisciplinary discussion regarding the need for SLNB. RESULTS: In 437 patients with 442 cancers, the median patient age was 63 years, median mammographic tumor size was 0.9 cm, and 74% were grade 2. A total of 34 patients (8%) had high-risk features on final pathology (grade 3, n=20; T≥3 cm, n=11; HER2+, n=3) and 14 (3.2%) had SLNB. Of these, 2 had SLN metastases. A total of 96% of patients received radiotherapy (40% whole breast, 56% partial breast), 415 (95%) received adjuvant endocrine therapy, and 31 (7%) received chemotherapy. At 7.7-month median follow-up, there have been no axillary recurrences. CONCLUSION: Adoption of the SOUND, INSEMA, and BOOG 13-08 data allowed omission of SLNB in 97% of postmenopausal patients age ≤70 years with cT1-2N0, grade 1/2, HR+/HER2- cancers and a normal AUS, reducing the burden of treatment.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Allen LR, Plitas G, Sawka R, et al. De-escalation of Axillary Surgery in Early Breast Cancer: Translating SOUND and INSEMA into Clinical Practice. Ann Surg. 2026. PMID: 42860587. doi:10.1097/SLA.0000000000007232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。